TY - JOUR
T1 - The potential for treg-enhancing therapies in nervous system pathologies
AU - Olson, Katherine E.
AU - Mosley, R. L.
AU - Gendelman, Howard E.
N1 - Funding Information:
The authors would like to thank the series editor, Dr. David Tough, for allowing us to contribute to this review series. We would also like to thank BioRender for use of their graphics program and the INBRE grant from NIH (2P20GM103427) for supporting a site license to EndNote software.
Funding Information:
This work is supported by the University of Nebraska Foundation, which includes community donations from the Carol Swarts, M.D. Emerging Neuroscience Research Laboratory, the Margaret R. Larson Professorship, the Eisenberg Parkinson’s Research Fund, and the Frances and Louie Blumkin and Harriet Singer Research Foundations and National Institutes of Health grants P01 DA028555, R01 NS36126, P01 NS31492, P01 MH64570, P01 NS43985, P30 MH062261, and R01 AG043540 (HEG), and 2R01 NS034239 (HEG and RLM)
Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press on behalf of the British Society for Immunology. All rights reserved.
PY - 2023/2
Y1 - 2023/2
N2 - While inflammation may not be the cause of disease, it is well known that it contributes to disease pathogenesis across a multitude of peripheral and central nervous system disorders. Chronic and overactive inflammation due to an effector T-cell-mediated aberrant immune response ultimately leads to tissue damage and neuronal cell death. To counteract peripheral and neuroinflammatory responses, research is being focused on regulatory T cell enhancement as a therapeutic target. Regulatory T cells are an immunosuppressive subpopulation of CD4+ T helper cells essential for maintaining immune homeostasis. The cells play pivotal roles in suppressing immune responses to maintain immune tolerance. In so doing, they control T cell proliferation and pro-inflammatory cytokine production curtailing autoimmunity and inflammation. For nervous system pathologies, Treg are known to affect the onset and tempo of neural injuries. To this end, we review recent findings supporting Treg's role in disease, as well as serving as a therapeutic agent in multiple sclerosis, myasthenia gravis, Guillain-Barre syndrome, Parkinson's and Alzheimer's diseases, and amyotrophic lateral sclerosis. An ever-broader role for Treg in the control of neurologic disease has been shown for traumatic brain injury, stroke, neurotrophic pain, epilepsy, and psychiatric disorders. To such ends, this review serves to examine the role played by Tregs in nervous system diseases with a focus on harnessing their functional therapeutic role(s).
AB - While inflammation may not be the cause of disease, it is well known that it contributes to disease pathogenesis across a multitude of peripheral and central nervous system disorders. Chronic and overactive inflammation due to an effector T-cell-mediated aberrant immune response ultimately leads to tissue damage and neuronal cell death. To counteract peripheral and neuroinflammatory responses, research is being focused on regulatory T cell enhancement as a therapeutic target. Regulatory T cells are an immunosuppressive subpopulation of CD4+ T helper cells essential for maintaining immune homeostasis. The cells play pivotal roles in suppressing immune responses to maintain immune tolerance. In so doing, they control T cell proliferation and pro-inflammatory cytokine production curtailing autoimmunity and inflammation. For nervous system pathologies, Treg are known to affect the onset and tempo of neural injuries. To this end, we review recent findings supporting Treg's role in disease, as well as serving as a therapeutic agent in multiple sclerosis, myasthenia gravis, Guillain-Barre syndrome, Parkinson's and Alzheimer's diseases, and amyotrophic lateral sclerosis. An ever-broader role for Treg in the control of neurologic disease has been shown for traumatic brain injury, stroke, neurotrophic pain, epilepsy, and psychiatric disorders. To such ends, this review serves to examine the role played by Tregs in nervous system diseases with a focus on harnessing their functional therapeutic role(s).
KW - autoimmunity
KW - inflammation
KW - neurodegenerative disease
KW - neuroimmunology
KW - regulatory T cells
UR - http://www.scopus.com/inward/record.url?scp=85150666845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85150666845&partnerID=8YFLogxK
U2 - 10.1093/cei/uxac084
DO - 10.1093/cei/uxac084
M3 - Review article
C2 - 36041453
AN - SCOPUS:85150666845
SN - 0009-9104
VL - 211
SP - 108
EP - 121
JO - Clinical and Experimental Immunology
JF - Clinical and Experimental Immunology
IS - 2
ER -